Potential control of risperidone-related cognitive deficits by adjunctive aripiprazole treatment by Hu, Chang-Hua et al.
University of Wollongong 
Research Online 
Faculty of Science, Medicine and Health - 
Papers: part A Faculty of Science, Medicine and Health 
2011 
Potential control of risperidone-related cognitive deficits by adjunctive 
aripiprazole treatment 
Chang-Hua Hu 
University of Wollongong 
Nagesh Pai 
University of Wollongong, nagesh@uow.edu.au 
Xu-Feng Huang 
University of Wollongong, xhuang@uow.edu.au 
Chao Deng 
University of Wollongong, chao@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/smhpapers 
 Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences 
Commons 
Recommended Citation 
Hu, Chang-Hua; Pai, Nagesh; Huang, Xu-Feng; and Deng, Chao, "Potential control of risperidone-related 
cognitive deficits by adjunctive aripiprazole treatment" (2011). Faculty of Science, Medicine and Health - 
Papers: part A. 1391. 
https://ro.uow.edu.au/smhpapers/1391 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Potential control of risperidone-related cognitive deficits by adjunctive 
aripiprazole treatment 
Abstract 
We have read with great interest Uchida and colleagues’ paper in your journal (2009; 29: 571–576), which 
reported that a high dosage of risperidone had a negative impact on cognition in older patients with 
schizophrenia. This finding is consistent with that of a previous study of a younger patient group showing 
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Editors, 
We have read with great interest Uchida and colleagues’ paper in your journal (2009; 
29: 571–576), which reported that a high dosage of risperidone had a negative impact 
on cognition in older patients with schizophrenia1. This finding is consistent with that 
of a previous study of a younger patient group showing that schizophrenia patients 
under high antipsychotic dosage have poor cognitive function performance2. One key 
issue is how to control risperidone related attention deficit. Uchida and colleagues 
suggested minimizing the adverse effects of risperidone on cognitive function by 
identifying/using the lowest effective dose of antipsychotics in schizophrenia patients1. 
Although very valuable, a low dosage of risperidone may also cause adverse effects 
on cognitive function3, which could be particularly problematic in aged patients due 
to age-related pharmacodynamic and pharmacokinetic changes4. It is very important 
that Uchida and colleagues identified that attention deficits induced by risperidone 
negatively correlated with dopamine D2 receptor blockade1. We propose that an 
adjunctive aripiprazole administration with rispirdone could be an effective method to 
control risperidone related attention deficits (and other cognitive deficits) through 
improving D2 receptor activity.  
 
Aripiprazole is a newly introduced antipsychotic drug that has a favourable safety and 
tolerability profile5, particularly in the elderly patients4. Aripiprazole was developed 
as a potent D2 partial-agonist, 5-HT1A partial-agonist, and also 5-HT2A antagonist
4, 
however, recent studies have suggested that aripiprazole is not a simple 
partial-agonist, but a functionally selective drug that can act as a D2 agonist or D2 
antagonist depending on different brain regions6,7. It is possible that aripiprazole could 
be used to control risperidone related attention deficits (caused by dopamine D2 
receptor blockage) through its D2 agonistic effect. In fact, aripiprazole can 
preferentially increase dopamine release in the medial prefrontal cortex and 
hippocampus8 and dopamine synthesis in the nucleus accumbens6. A recent study has 
shown that typical antipsychotic treatment resulted in hypoactivation in the dorsal 
anterior cingulated cortex, which could be improved after switching to aripiprazole 
and is correlated with improved performance of working memory9. Findling et al.10 
examined the effectiveness and cognitive effects of aripiprazole in children with a 
primary diagnosis of attention-deficit/hyperactivity disorder (ADHD), and showed 
that aripiprazole led to clinical benefit in reducing ADHD symptoms and improving 
cognition functioning. Moreover, adjunctive aripiprazole treatment has been trialled 
in risperidone related hyperprolactinemia11,12 and olanzapine/clozapine-induced 
obesity13,14. These studies showed that adjunctive treatment using aripiprazole with 
other antipsychotics (such as risperidone and olanzapine) was generally safe and well 
tolerated, and is effective even without reducing the original doses of other 
antipsychtotics4,11,13,14. Therefore, co-administration of aripiprazole and risperidone 
will result in multiple pharmacological actions and improve the adverse effects 
beyond the attention deficits (such as weight gain15). Of course, further animal studies 
and clinical trials are necessary for testing adjunctive aripiprazole/risperidone 
treatment, especially in elderly patients that are at increased risk from drug–drug 
interactions. 
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